CHARLOTTESVILLE, Va. (WDBJ) - A recent study by the University of Virginia School of Medicine is finding a new approach to boosting vaccination rates for older adults.

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

In fact, the share price is now only right around ... The company is currently working on vaccines for RSV and the seasonal flu, as well as some rare diseases. However, right now, it is still ...

The reason I'm going to quote you directly from Slack here, David, the most uncertain revenue guidance I've ever seen. You care to elaborate on that? David Meier: Yes. I've been doing this a long time ...

The RSV vaccine, this is not my ... absolute war chest of cash on their balance sheet. They will be able to get through this period because of the fact that they've been smart in terms of how ...